Amgenvs.Vertex Pharmaceuticals
AMGN vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 1.6× larger than Vertex Pharmaceuticals by market cap; Amgen trades at the lower P/E (25.1 vs 27.9); year to date, Amgen leads (+11.0% vs +7.1%).
Side by side
| AMGN | VRTX | |
|---|---|---|
| Market cap | $196B | $121B |
| Price | $363.39 | $485.39 |
| Today | −0.1% | −2.2% |
| Return YTD | +11.0% | +7.1% |
| Return 1Y | +21.0% | +1.2% |
| P/E | 25.1 | 27.9 |
| P/S | 5.3 | 9.9 |
| P/B | 21.3 | 6.3 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AmgenAMGN
Veteran American biotech with a broad portfolio in oncology, immunology and bone diseases — and an obesity candidate (MariTide) in the pipeline.
Full AMGN profile →Vertex PharmaceuticalsVRTX
American biotech company and global leader in cystic fibrosis treatment, with a pipeline in pain and gene therapy.
Full VRTX profile →More comparisons in Biotech & innovation
See where AMGN and VRTX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →